Update and make a note
$SNTI.US$ Senti Biosciences Announces $8M CIRM Grant To Support Clinical Development Of SENTI-202 CAR-NK Cell Therapy For Hematologic Malignancies; First Tranche Expected In August 2024; Phase 1 Trial Enrolling Patients In US And Australia, Initial Efficacy Data Anticipated By Year-End 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
